Positive results from Sigrid Therapeutics proof-of-concept prediabetes STAR study published in Nanomedicine
Home HEALTHCARE Positive results from Sigrid Therapeutics proof-of-concept prediabetes STAR

Positive results from Sigrid Therapeutics proof-of-concept prediabetes STAR

Published by Editorial

First-in-Class Medical Device SiPore15® – based therapy significantly reduced long-term blood sugar levels and improved metabolic parameters in prediabetics.

Sigrid Therapeutics AB, an innovative technology company developing a new class of silica-based therapies for metabolic diseases and disorders, today announce that the results from their Proof-of-Concept STAR study have been published in Nanomedicine.

Oral administration of the Company’s lead product SiPore15® to subjects with prediabetes or newly diagnosed type 2 diabetes resulted in a significant and clinically meaningful reduction in HbA1c, a key marker of glucose control. The treatment also improved several disease-associated parameters while side effects were minimal. The news follows the recent, over-subscribed capital raise and the signing of a major manufacturing deal with Japan’s AGC for production of SiPore15®.

Positive results from Sigrid Therapeutics proof-of-concept prediabetes STAR study published in Nanomedicine

Tore Bengtsson

The main finding of this study was that SiPore15® treatment in individuals with prediabetes or newly diagnosed type 2 diabetes significantly reduced HbA1c levels to a clinically relevant degree. The HbA1c level was significantly reduced in the all-participants group (N=38) after 6 weeks of SiPore15® treatment (p = 0.0025) and showed a significant decreasing trend over the entire 12-week treatment period (p = 0.0209). Reduction in HbA1c level in prediabetics and newly diagnosed type 2 diabetics was independent of body weight and BMI.

In one group of patients, HbA1c levels significantly decreased by 1.04 mmol/mol from baseline after 6 weeks and was further reduced to 1.44 mmol/mol after 12 weeks of SiPore15® administration. This magnitude of reduction has been shown to reduce diabetes incidence in prediabetics by 31%  and is comparable to what has been achieved by a currently advised scheme for the treatment of prediabetes.

“This Proof-of-Concept study in humans confirms the results from our First in Man study and preclinical research ”, says Tore Bengtsson, Professor at Stockholm University, co-founder and CSO of Sigrid Therapeutics. “The results from this study demonstrate the potential use of SiPore15® as a treatment for prediabetes that may also delay or prevent the onset of type 2 diabetes.”

Sana Alajmovic, Co-Founder & CEO of Sigrid Therapeutics, comments: “We are delighted to see that the results of our STAR trial has been published in such a prestigious peer-reviewed scientific journal as Nanomedicine. We recently raised $8.4 million to be used for a pivotal, placebo-controlled, double-blind, multicenter clinical study called SHINE that will form the basis for CE-marking in the EU and is set to start enrolling patients the second half of 2022.”

 

 

 

Related Posts

We use cookies to improve user experience, and analyze website traffic. For these reasons, we may share your site usage data with our analytics partners. By clicking “Accept Cookies,” you consent to store on your device all the technologies described in our Cookie Policy. Accept Read More